

BostonSight Holds Eighth Annual FitAcademy Retreat for Cornea and Contact Lens Residents and Fellows

NEEDHAM, MA, UNITED STATES,
September 29, 2026 /

EINPresswire.com/ -- BostonSight®, a nonprofit eye healthcare organization, held its 8th annual [FitAcademy®](#) Retreat for Cornea and Contact Lens Residents and Fellows at New England College of Optometry ([NECO](#)) in Boston, September 11-12, 2026.

FitAcademy for Residents is a core component of BostonSight's educational arm as BostonSight continues to expand access to scleral lenses and clinical care training around the world. This year, 28 cornea and contact lens residents and fellows from sites throughout the United States and Canada attended the event, which

focused on strategies to fit and troubleshoot scleral lenses, and centered on a staple of FitAcademy programs – the importance of the eye's physiological function and the Beyond the Fit® medical management of the scleral lens patient. The retreat also included a hands-on wet lab and scleral lens application and removal training.

"Our sponsors allow us to host this event at little to no cost to the attendee and for that we're extremely grateful. Thank you to NECO, [Glaukos](#) Corporation, Lenz Therapeutics, Contamac, Tangible Science, John and Linda Henry and the Boston Red Sox, and Evan J. Haberman," said Karen G. Carrasquillo, OD, PhD, FAAO, FSLS, FBCLA, BostonSight's Chief Innovation and Education Officer and founder and director of FitAcademy programs. "Their support demonstrates their commitment to early career education for specialty lens optometrists and positively impacting patient outcomes."

FitAcademy is led by Dr. Carrasquillo and was taught this year by BostonSight staff Bitu Asghari,



OD, FAAO, FSLs, Associate Director of Education; Michelle Kong, OD; Chirag Patel, OD, FAAO, Director of Innovative Technologies; and Daniel Brocks, MD, Chief Medical Officer and Cornea Specialist. The invited faculty included Gloria Chiu, OD, FAAO, FSLs, Associate Professor of Clinical Ophthalmology at the USC Roski Eye Institute; Clark Y. Chang, OD, MSA, MSc, FAAO, FSLs, Director of Specialty Contact Lenses in Cornea Service at Wills Eye Hospital and Senior Director of Medical and Surgical Operations at EssilorLuxottica ; Rutvi Doshi, OD, FAAO, FSLs, Global Medical Director for Cornea at Glaukos; Anita Gulmiri, OD, FAAO, FSLs, Associate Medical Director Lenz Therapeutics and Adjunct Faculty at NECO; and Jennifer Liao, OD, FAAO, FSLs, Associate Professor of Optometry and Residency coordinator of the Cornea and Contact Lenses Residency Program at NECO.

Each year, invitations are sent to residency sites from BostonSight. If you are a cornea and contact lens residency director and would like to be added to our invite list, please visit <https://www.bostonsight.org/practitioners/education/fitacademy/>

About NECO

New England College of Optometry is a private, nonprofit, and internationally recognized optometry school. We prepare the next generation of eye care providers, educators, and innovators through rigorous curriculum, extensive clinical experiences, state-of-the-art facilities, and a strong support network. As an independent optometry school, we focus solely on optometry. Founded in 1894, NECO is the oldest continuously operating optometry school in the U.S. and has been advancing optometric education ever since.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

About BostonSight®

BostonSight is a global eye healthcare nonprofit advancing specialty lens care in service of patients and the professionals who care for them. Our ongoing commitment to research and achieving optimal patient outcomes via innovative specialty lens designs, education, and technology has saved the sight of thousands of people around the world. Learn more at www.bostonsight.org

Michele Hart
BostonSight
+1 781-675-9872

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/946090494>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.